{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:15:47Z","timestamp":1790874947704,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.amjmed.2008.12.003","type":"journal-article","created":{"date-parts":[[2009,1,31]],"date-time":"2009-01-31T04:16:50Z","timestamp":1233375410000},"page":"S14-S21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"special_numbering":"S","title":["Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis"],"prefix":"10.1016","volume":"122","author":[{"given":"John P.","family":"Bilezikian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2008.12.003_bib2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2008.12.003_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","article-title":"Requirements for DXA for the management of osteoporosis in Europe","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2008.12.003_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2008.12.003_bib5","series-title":"Clinician's Guide to Prevention and Treatment of Osteoporosis","year":"2008"},{"key":"10.1016\/j.amjmed.2008.12.003_bib6","series-title":"Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group","year":"1994"},{"key":"10.1016\/j.amjmed.2008.12.003_bib7","series-title":"Assessment of Osteoporosis at the Primary Health-Care Level","author":"Kanis","year":"2007"},{"key":"10.1016\/j.amjmed.2008.12.003_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ncpendmet0121","article-title":"Drug insight: bisphosphonates for postmenopausal osteoporosis","volume":"2","author":"Chapurlat","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2008.12.003_bib10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2008.12.003_bib11","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2008.12.003_bib12","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX)","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2008.12.003_bib13","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"key":"10.1016\/j.amjmed.2008.12.003_bib14","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2008.12.003_bib15","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2008.12.003_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2008.12.003_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"S\u00f6rensen","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.amjmed.2008.12.003_bib18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstr\u00f6m","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.amjmed.2008.12.003_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2008.12.003_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.amjmed.2008.12.003_bib21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1185\/030079904125003566","article-title":"Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis","volume":"20","author":"Harris","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjmed.2008.12.003_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","article-title":"Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis","volume":"42","author":"Delmas","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.amjmed.2008.12.003_bib23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2008.12.003_bib24","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjmed.2008.12.003_bib25","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing Intravenous Administration Study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2008.12.003_bib26","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2008.12.003_bib27","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934308011911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934308011911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:49:27Z","timestamp":1757580567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934308011911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0002934308011911"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2008.12.003","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2008.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}